Table 1 Participants’ clinical characteristics—Cohort-NA versus Cohort-A

Ishak stage [n (%)]

 0

143 (20.1)

5 (6.2)

 < 0.001

 1

164 (23.1)

7 (8.6)

 2

110 (15.5)

6 (7.4)

 3

99 (13.9)

4 (4.9)

 4

64 (9.0)

5 (6.2)

 5

51 (7.2)

10 (12.3)

 6

75 (10.6)

44 (54.3)

ELF score [n(%)]

≧ 8.3

379 (53.8)

74 (91.4)

 < 0.001

≧ 9.8

128 (18.2)

59 (72.8)

≧ 10.5

79 (11.2)

49 (60.5)

≧ 11.3

40 (5.7)

38 (46.9)

Male gender [n (%)]

456 (64.7)

55 (67.9)

0.595

Age [median (IQR)]

43.0 (35.0–54.5)

50.0 (41.5–57.5)

 < 0.001

ALT (IU/L) [median (IQR)]*

55 (31–93)

36 (23–66)

 < 0.001

Platelet count (10⁹/L) [median (IQR)]^

203 (159–249)

162 (105–220)

 < 0.001

Bilirubin (umol/L) [median (IQR)]⁺

12 (9–16)

20 (11–102)

 < 0.001